Review

Look in or book in: The case for type 2 diabetes remission to prevent diabetic retinopathy

John Cripps, Mark Cucuzzella
Journal of Metabolic Health | Vol 6, No 1 | a79 | DOI: https://doi.org/10.4102/jir.v6i1.79 | © 2023 John Cripps, Mark Cucuzzella | This work is licensed under CC Attribution 4.0
Submitted: 03 November 2022 | Published: 11 April 2023

About the author(s)

John Cripps, Department of General Surgery, Northern Ontario School of Medicine, Sudbury, Canada
Mark Cucuzzella, WVU Center for Diabetes and Metabolic Health, Faculty of Medicine, West Virginia University, Martinsburg, United States of America

Abstract

Background: Diabetic retinopathy (DR) remains the leading cause of legal blindness in 18- to 74-year-old Americans and in most developed nations. Screening for DR has increased minimally over four decades.

Aim: Primary care physicians are critical to improve both visual and systemic outcomes in patients with diabetes. Diabetic retinopathy screening affords clinicians the opportunity to discuss type 2 diabetes (T2D) remission with patients. Primary care is well positioned to manage, and lower risks, of the systemic-associated diseases predicted by DR. The goal of this review was to assess the current literature on DR, new technology to enhance primary care-based screening, and the science and practical application of diabetes remission. A two-pronged strategy, bringing attention to ophthalmologists the potential of diabetes remission, and family physicians, the importance of retinopathy screening, may reduce the prevalence of blindness in patients with diabetes.

Methods: Embase, PubMed, Google Scholar, AMED, and MEDLINE databases were searched using keywords ‘diabetic retinopathy; diabetic retinopathy screening, diabetes remission, diabetes reversal, and AI and diabetic retinopathy’.

Results: Robust literature now exists on diabetes remission and international consensus panels are aligning on the strategies and the definition.

Conclusion: Diabetic retinopathy remains the leading cause of legal blindness. Novel primary care friendly imaging would benefit nearly half of Americans from earlier detection and treatment of DR still not receiving such care. The most powerful way a primary care clinician could impact DR would be assisting in making the T2D go into remission. Prevention or slowing of progression of DR would greatly improve both visual and systemic outcomes patients with diabetes.

Contribution: This article highlights the importance of addressing DR and metabolic health to reduce not only the eye effects of T2D but the multisystem complications.


Keywords

diabetic retinopathy; diabetic retinopathy screening; diabetes remission; diabetes reversal; AI and diabetic retinopathy

Metrics

Total abstract views: 2452
Total article views: 3766


Crossref Citations

No related citations found.